Citation & Authors
JAMA Netw Open. 2024;7(1):e2350050.
ABSTRACT · CHINESE TRANSLATION
Translated abstract
Translated from the licensed abstract via the Chinese version. This is not an official journal translation.
importance
Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are associated with better kidney and cardiovascular outcomes in patients with type 2 diabetes, but their associations in patients with both type 2 diabetes and acute kidney disease (AKD) remain unclear.
purpose
To examine associations of SGLT2i use with long-term mortality, major adverse kidney events (MAKE), and major adverse cardiovascular events (MACE) in patients with type 2 diabetes and AKD.
Design, site and participants
This cohort study used global healthcare data from the TriNetX database between September 30, 2002, and September 30, 2022, selecting patients through propensity score matching. Follow-up continued for up to 5 years, until September 30, 2022, or until an outcome or death occurred.
intervene
SGLT2i use.
Main outcomes and measures
The primary outcomes were death, MAKE, and MACE. Adjusted hazard ratios (AHRs) and 95% confidence intervals were calculated to compare users with nonusers and estimate the average treatment effect among the treated.
result
The cohort included 230,366 patients with AKD, with a mean age of 67.1 years (SD 16.4); 51.8% were male and 48.2% female. Median follow-up was 2.3 years (IQR 1.2–3.5). Of these patients, 5,319 (2.3%) used SGLT2i. Among nonusers, the proportions experiencing death, MAKE, and MACE were 18.7%, 21.0%, and 25.8%, respectively. After propensity score matching, absolute differences between groups in these outcome proportions were 9.7, 11.5, and 12.3 percentage points. Estimating effects among the treated, SGLT2i use was significantly associated with lower risks of death (AHR 0.69; 95% CI 0.62–0.77), MAKE (0.62; 0.56–0.69), and MACE (0.75; 0.65–0.88). External validation in a multicenter cohort including 1,233 patients with AKD receiving SGLT2i supported these favorable associations. Risk reductions remained statistically significant even in patients without hypertension or advanced chronic kidney disease, or without other glucose-lowering medications.
Conclusion and significance
In this cohort with type 2 diabetes and AKD, SGLT2i use was associated with significant reductions in all-cause mortality, MAKE, and MACE compared with nonuse, highlighting its relevance to care after acute kidney injury. The findings support potential benefits of SGLT2i in AKD management and in reducing major cardiovascular and kidney disease risks.
Original work: Author of the above paper. Source:Public Summary ↗. This translation is based on the Chinese rendering of the original English abstract.
Original work license:CC BY ↗;Translations are subject to the same licensing conditions.
